Using subtractive immunization to identify cell surface epitopes expressed in a metastasis-speci®c fashion on cells of the rat MT-W9 mammary carcinoma model, we generated a monoclonal antibody called M-N#1. This antibody binds speci®cally to metastasizing cells of the MT-W9 series and also to certain other metastasizing rat mammary carcinoma cell lines. We demonstrate that the M-N#1 antibody recognizes a fucosylated N-glycosyl sugar modi®cation, and furthermore show that the epitope speci®city of the M-N#1 antibody is for blood group antigen B subtypes 2, 3 and 4 with slight crossreactivity with blood group antigen A subtype 2. The expression of these carbohydrate epitopes on MT-450 cells is functionally important, because the M-N#1 antibody eciently inhibits MT-450 tumour growth in spontaneous metastasis assays. These results suggest that expression of the subtypes of blood group antigen B recognized by the M-N#1 antibody does not directly participate in the metastatic cascade but rather confers a growth or survival advantage on the tumour cells.
Introduction
Aberrant posttranslational carbohydrate modi®cation of proteins and sphingolipids is functionally important during tumorigenesis (reviewed in Hakomori, 1996) . In several cases, changes in glycosylation modulate the function of proteins implicated in tumour progression. For example, the adhesive properties of E-cadherin are dependent on the type of N-linked glycosylation with which it is modi®ed (Yoshimura et al., 1996) . The function of integrins is also controlled by N-linked glycosylation (Akiyama et al., 1989; Chammas et al., 1991; Zheng et al., 1994) . Carbohydrate modi®cations can additionally act directly as adhesion or antiadhesion molecules. Aberrant glycosylation can therefore in this way also alter the adhesive properties of tumour cells (Hakomori, 1996) .
Changes in expression of the class of cell surface carbohydrates called blood group antigens have been documented during tumour progression (reviewed in Clausen and Hakomori, 1989; Hakomori, 1996; King, 1994) , and can have prognostic signi®cance (e.g. Miyake et al., 1992) . A signi®cant amount of evidence suggests a role for altered ABH antigen expression in certain tumours, particularly of the colon. Expression of A and H blood group antigens changes during tumour progression of chemically-induced colorectal carcinoma in rats (Hallouin et al., 1998) . Moreover, experimental modi®cation of the expression of H antigens on colonic carcinoma tumour cells alters their tumorigenicity (Labarriere et al., 1994; Goupille et al., 1997) . Upregulation of ABH blood group antigens has been described in subsets of human colonic carcinomas, although loss of expression and structural changes also occurs (Yuan et al., 1985; Schoentag et al., 1987; Dabelsteen et al., 1988) . Upregulation in carcinomas of the distal colon represents a return to foetal patterns of expression (Yuan et al., 1985; Dabelsteen et al., 1988; Denk et al., 1974) , and thus ABH antigen expression at least in these tumours can be considered as oncofoetal. Until now, however, a functional role for changed blood group B antigen expression in tumours has not been demonstrated.
The physiological and pathological function of ABH blood group antigens remains obscure. ABH antigens are expressed on glandular epithelia, neurones and in exocrine secretions, and are carried on N-or O-linked sugar modi®cations of glycoproteins and glycosphingolipids, or are present as free oligosaccharides (reviewed in Clausen and Hakomori, 1989; King, 1994) . Only humans and certain primates carry ABH antigens on endothelial cells and on erythrocytes (Oriol et al., 1984) , where in the latter case they have a histocompatibility function.
Clinically, the critical end point of tumour progression is the acquisition of metastatic potential. Changes in the complement of surface antigens expressed by tumour cells must be crucial during progression to metastatic competence, as these mediate contact with other cells and extra-cellular matrix surfaces necessary to allow the tumour cells to migrate through the body. Our aim in this study was to identify metastasis-speci®c surface markers expressed on a series of clones of the MT-W9 mammary carcinoma model which dier in their metastatic proclivity (Kim, 1986) . Speci®cally, we generated monoclonal antibodies directed against metastasizing tumours of the MT-W9 series using subtractive immunization (SI). This technique effectively enriches the immune response against antigens present on one cell type but not another (Byrne and Cox, 1986; Vermeersch et al., 1992) , and provides a means for both identifying and analysing metastasisrelated cell surface antigens (Brooks et al., 1993) . A monoclonal antibody we generated called M-N#1 binds to a carbohydrate antigen carried by N-linked sugars which is structurally equivalent to subtypes of blood group B. The antibody has a powerful inhibitory eect on the growth of MT-450 mammary tumours in vivo, demonstrating a functional role for subtypes of blood group antigen B in tumour growth.
Results
Production by SI of monoclonal antibodies which bind to metastasizing tumour cells Using SI, we produced monoclonal antibodies which speci®cally bind to cell surface antigens expressed on metastatic clones of MT-W9-derived tumour cell lines. In SI, B cells which proliferate in response to immunization with one cell type (the tolerogen) are killed by cyclophosphamide. Subsequent immunization with the other cell type (the immunogen) results in a humoral response directed against antigens found only on the immunogen. Mice were subtractively immunized with non-metastatic NM-081 cells as the tolerogen followed by highly metastatic MT-450 cells as the immunogen. Prebleeds and test bleeds taken after the tolerization and immunization steps were assayed by cell ELISA using NM-081 and MT-450 cells as targets. None of the surviving mice showed an immune response to the tolerogen 10 days after the second series of cyclophosphamide treatments. Furthermore, all of these mice showed an enhanced reactivity towards the immunogen after completion of the immunization schedule (data not shown), consistent with previously published results (Brooks et al., 1993) .
Spleen cells from immunized mice were used to generate hybridomas. None of the hybridomas produced antibodies which recognized the tolerogen alone, demonstrating the eectiveness of the SI. One of the hybridomas secreted an antibody designated M-N#1 which reacted strongly and exclusively with the highly metastatic MT-450 cells (Figure 1 ). To begin to determine whether M-N#1 antigen expression may be of relevance to tumour progression, we screened for the ability of the M-N#1 antibody to stain sections of tumours derived from rat MT-W9 mammary tumour lines of diering metastatic potential. Here, M-N#1 maintained a progression-related staining pattern (Figure 2) . The non-metastasizing tumours MT-W9A and MT-W9B showed no or only weak diuse staining. However, in the metastasizing MT-449 tumours, clusters of cells within the tumour were strongly stained. Furthermore, strong M-N#1 staining was observed throughout the metastasizing MT-450 tumours. Rat carcinoma cells lines of various origin were stained with the M-N#1 antibody (Table 1) . Of these, none of the cell lines with low metastatic potential were stained. Few of the metastasizing mammary carcinoma cell lines stained with the M-N#1 antibody, suggesting that M-N#1 antigen expression is not obligatory for metastasis of mammary carcinoma cells. The antibody bound strongly to two of the metastasizing cell lines (MTLy and MAT B III), but only 10 ± 20% of the cells were stained, in contrast to the homogenous staining of MT-450 cells. Using FACS sorting, we cloned MTLy cells expressing homogenously high levels of the M-N#1 antigen. However, after a few passages the staining pattern of the sorted cells returned to only 10 ± 20% of the cells being strongly positive for the M-N#1 antigen (data not shown), suggesting that in this cell line M-N#1 expression is non-constitutive.
In addition to investigating the expression of the M-N#1 antigen in tumour cells, we examined its Table 2 ). The epithelia of the corpus and antrum regions of the stomach were strongly stained, as were acinal cells of the pancreas. Cells at the base of crypts were stained throughout the intestine. However, only a proportion of crypts contain cells which were stained by the antibody. In salivary glands, occasional cells in the mucous alveoli were stained. Cervical epithelium was also weakly stained. These data suggest that constitutive M-N#1 expression is largely characteristic of epithelia with glandular characteristics, although intense staining was also observed throughout the bone marrow. (Figure 5a ). Furthermore, Ulex Europaea lectin (which binds fucosylated sugars) was also used to purify fucosylated 35 S-labelled proteins from lysates of MT-450 cells. The M-N#1 antibody was able to precipitate protein from this puri®ed material ( Figure  5b) . Treatment of the M-N#1-precipitated protein with N-glycosidase F altered its migration pattern as previously observed. These data demonstrate that fucose is a constituent of the N-linked sugar which bears the M-N#1 antigen.
Identi®cation of the M-N#1 antigen as subtypes of blood group B
The biochemical nature of the M-N#1 antigen and its staining pattern in normal tissues strongly suggested that the M-N#1 antigen is a blood group antigen. Indeed, we found that the M-N#1 staining pattern of human erythrocytes and tissues is blood group restricted ( Figure 6 , Table 3 , data not shown). The reactivity of antibody M-N#1 was tested on ten dierent human gastro-duodenal mucosae of known ABO, Lewis and Secretor phenotypes. Phenotypes of the donors were: A Le(a+b7), A Le(a7b+), A Le(a7b7), AB Le(a7b+), B Le(a+b7), B Le(a7b+), O Le(a+b7), O Le(a7b+), O Le(a7b7). The 3 Le(a7b7) donors were secretors of A and H in the gastro-duodenal junction. M-N#1 bound to erythrocytes and vascular endothelium of B and AB individuals irrespective of their secretor or Lewis phenotype and reacted with the pyloric and duodenal epithelia of blood group B individuals according to secretor status. It stained the surface epithelial cells of the pylorus of A secretor individuals but not the duodenum, jejunum, erythrocytes or vascular endothelium, and stained no tissues from A non-secretor or O individuals. The antibody thus behaves as an anti-B blood group reagent with some cross-reactivity to A antigen detectable when the latter antigen is present in large amounts as in the pyloric surface epithelium of A secretors.
To con®rm the epitope speci®city of the M-N#1 antibody, the antibody was used in ELISA experiments using human blood group B saliva as the target. Solid phase synthetic blood group sugars of dierent speci®cities were used to adsorb M-N#1 antibody before its addition to the target. In this way, sugars which adsorbed out the M-N#1 antibody were identi®ed as epitopes bound by the M-N#1 antibody. Binding of M-N#1 antibody to the target was blocked by blood group B sugars types 2, 3 and 4, and partially by blood group A type 2 ( Table 4 ). Blocking of binding was dependent on fucose linked in alpha 1 ± 2.
These data de®ne the M-N#1 antigen as blood group B subtypes 2, 3 and 4 with cross-reactivity towards blood group A subtype 2.
M-N#1 antibody blocks tumour growth in vivo
Although staining of tumour cells with the M-N#1 antibody in some cases correlated with metastatic progression of mammary carcinoma cells, this fact alone does not mean that M-N#1 antigen expression necessarily plays any role in tumour progression. We reasoned that inhibition of tumour growth or metastasis in vivo by the M-N#1 antibody would speak for a functional role in these processes for the antigen bound by the M-N#1 antibody. Therefore we M-N#1 antibody (0.2 mg) was incubated for 1 h on 10 mg of beads to which various oligosaccharides were attached (see Table 4a ). Supernatants were collected and remaining antibody was tested by an ELISA against B saliva as described in Materials and methods. Non speci®c adsorption was tested using beads to which no oligosaccharides were coupled (control). Percentages of adsorption were obtained from the ratio of the signals given by antibody adsorbed on beads to that given by non adsorbed antibody. No adsorption was detectable on beads coupled to all the other structures listed in Table 4a Figure 7 Primary tumour size (a) and survival (b) of Wistar Furth rats subcutaneously injected with 5610 5 MT-450 cells and treated with isotype control (1B7) or M-N#1 antibodies (see text for details of number of animals used). Tumour cells were injected in 100 ml PBS containing either 20 mg antibody (20 mg initial) or 200 mg antibody (200 mg initial). The rats were then treated with 200 mg antibody each twice weekly for 4 weeks. Rats were killed when moribund or when the size of the primary tumour exceed the German legal limit. In a, only rats in which tumours grew were included in the calculation of the average size of the primary tumour for the`1B7' and`M-N#1, 20 mg initial' curves, to avoid introducing bias due to dierences in the numbers of non-tumourbearing animals evaluated the eect of the M-N#1 antibody on the growth and metastasis of MT-450 tumours in vivo.
MT-450 cells were injected into the mammary fat pad of syngeneic female Wistar Furth rats, and the animals were treated with the M-N#1 antibody, or with an isotype-matched control (1B7) over a period of 4 weeks. In one set of experiments, 7/8 animals treated with the 1B7 antibody developed metastatic tumours which were ultimately fatal, while 0/8 animals treated with the M-N#1 antibody developed tumours. In another set of experiments, F(ab') 2 fragments of the M-N#1 antibody were also used to rule out complement ®xation and ADCC eects. Again, 7/8 animals treated with the 1B7 antibody or 1B7 F(ab') 2 fragments developed and died from metastatic tumours, while 0/8 developed tumours when treated with either intact M-N#1 antibody, or with M-N#1 F(ab') 2 fragments. In a third set of experiments, the initial dose of M-N#1 antibody was reduced to 20 mg/ rat. Here, 7/9 animals treated with the 1B7 antibody died from the growth of the injected tumour cells, while only 5/8 treated with the M-N#1 antibody did so. The remaining three rats did not develop tumours even after antibody treatment was discontinued. Furthermore, in those rats which developed tumours, the M-N#1 antibody signi®cantly retarded the appearance and reduced the growth of the primary tumours, retarded the onset of metastasis and prolonged the survival of the rats compared to those treated with the 1B7 antibody (Figure 7) . However, of the animals treated with M-N#1 and in which tumours grew, all subsequently developed metastases.
To rule out the possibility that contaminants in the M-N#1 antibody preparations used in the experiments were killing the tumour cells, we grew MT-450 cells in culture in the presence of up to 200 mg/ml M-N#1 antibody for 36 h. The eect of the antibody on the proliferation rate of the cells was then measured by thymidine incorporation. Even at the highest antibody concentrations no eect on the proliferation of the MT-450 cells was observed (data not shown).
These results clearly speak for a functional role for the M-N#1 antigen in tumour growth, and suggest that although its expression is associated with the metastatic phenotype, its signi®cance may be one of conferring a growth or survival advantage on the tumour cells in vivo.
Discussion
We have produced a monoclonal antibody called M-N#1 by subtractively immunizing mice with rat mammary carcinoma cells of dierent metastatic potential. The antibody binds to tumour cells in a progression-related manner. The M-N#1 antigen is carried by N-linked fucosylated glycosyl modi®cations of proteins expressed by the rat mammary carcinoma cell line MT-450, and is structurally equivalent to subtypes of blood group antigen B. The expression of the M-N#1 antigen by MT-450 cells is functionally important for tumour growth, because the M-N#1 antibody inhibits the formation of tumours from subcutaneously injected MT-450 cells in vivo.
The observation obtained with the M-N#1 antibody that ABH blood group antigens are upregulated during tumour progression of the rat MT-W9 mammary carcinoma model raises the possibility that these antigens may also be important in human mammary neoplasias. Conversely to our ®ndings in the rat MT-W9 model, several studies show that loss of expression of A and B antigens occurs during human breast tumour progression, although inappropriate A and B antigen in human mammary carcinomas has been reported in O individuals (Strauchen et al., 1980; Lee et al., 1985; Vowden et al., 1986; Ura et al., 1992) . The studies on ABH expression in human mammary tumours re¯ect the fact that we found very few rat tumour cells which express M-N#1 (Table 1) , suggesting that the upregulation of M-N#1 in the MT-W9 model may be paralleled in only a small subset of human tumours. Nevertheless, our data provide strong evidence that subtypes of blood group antigen B are functionally involved in the growth of MT-450 rat mammary tumours. This may also be relevant to the growth of human tumours such as colonic carcinomas where upregulated ABH expression is more widely observed.
The identi®cation and characterization of the protein(s) bearing the M-N#1 antigen in MT-450 cells will be vital for understanding how the antigen may function in tumour progression. The heavy glycosylation of the proteins bound by the M-N#1 antibody suggests they may be mucin-like, and there are many examples of tumour-related mucin expression (reviewed in Verma, 1994) . However, pan-speci®c antibodies against mucins failed to react with protein bearing the M-N#1 antigen (data not shown). Additionally, mucins are mainly O-glycosylated rather than N-glycosylated. Future work will focus on identifying the protein bearing the M-N#1 antigen in MT-450 cells.
ABH antigens are fucosylated structures, and the upregulation of the M-N#1 antigen in metastasizing cells of the MT-W9 mammary carcinoma model possibly re¯ects the documented upregulation of fucosyltransferase activity in metastasizing cells from the MT-W9 mammary carcinoma model (Chatterjee and Kim, 1978) . Upregulation of fucosyltransferase activity and subsequent fucosylation of carbohydrate precursors is correlated with tumour progression and poor prognosis (Holmes, 1990; Sun et al., 1995; Ogawa et al., 1996) . Furthermore, experimental modulation of a(1,2)fucosyltransferase activity can change the metastasizing properties of tumour cells (Labarriere et al., 1994; Goupille et al., 1997) .
How does M-N#1 antibody block tumour growth in vivo? Binding of the antibody should cross-couple cell surface proteins bearing the M-N#1 antigen, which in principle could induce transduction of tumorigenicityreducing signals. However, it is unlikely that apoptosis of the MT-450 cells or inhibition of their proliferation is directly induced by the M-N#1 antibody in vivo as the antibody does not induce apoptosis or inhibit proliferation of the cells in tissue culture. A more likely explanation is that the antibody inhibits the interaction of MT-450 cells with ligands or ECM components vital for their growth or survival in vivo. A candidate ligand would be galectin 3. This endogenous mammalian lectin binds to ABH antigens (Sato and Hughes, 1992) , has anti-apoptotic and growth-enhancing properties (Yang et al., 1996; Akahani et al., 1997) and can promote tumorigenicity and invasiveness (Raz et al., 1990; Le Marer and Hughes, 1996) . The possibility that M-N#1 antibody interferes with tumour growth by blocking the binding of molecules such as galectin 3 to MT-450 cells is one which we are currently investigating.
Materials and methods

Tissue culture cell lines
The NM-081 (Ghosh et al., 1983) and MT-450 (Kim, 1986) cell lines were cultured in DME supplemented with 10% FCS. The 1B7.11 hybridoma (ATCC TIB-191) which secretes mouse IgG1 anti-trinitrophenyl monoclonal antibodies was cultured in RPMI with 10% FCS. The culture conditions and properties of the other cell lines used in this paper have been previously described: MTLN2, MTLN3, MTC, MTLy, and MTPA (Neri et al., 1981; Lichtner and Nicolson, 1987), 13762 MAT B III (Xing and Rabbani, 1996) , AT1, AT2.1, AT3.1, AT6.1, MatLu, MatLyLu and G (Isaacs et al., 1978 (Isaacs et al., , 1986 Ichikawa et al., 1991 Ichikawa et al., , 1992 , ASML and 1AS (GuÈ nthert et al., 1991; Sleeman et al., 1996) and ARIP (ATCC CRL-1674).
Subtractive immunization
Tissue culture cells were harvested with PBS/5mM EDTA, then washed three times in PBS. For the subtraction, ten prebled female balbC/BL6 F1 hybrid mice were injected intradermally with 2610 6 NM-081 tissue culture cells (the tolerogen). After 24 and 48 h, 200 mg/kg cyclophosphamide was injected i.p. into each mouse. Three weeks later, the mice were again similarly injected with NM-081 cells and cyclophosphamide. Ten days later, test bleeds were taken. Three weeks after the last injection with NM-081 cells, 3610 6 MT-450 tissue culture cells (the immunogen) were injected intradermally. MT-450 cells were injected twice more after 3 week intervals. Ten days after the last immunization, test bleeds were taken. The test bleeds were compared together with the pre-bleeds in cell ELISAs using NM-081 and MT-450 cells as targets to identify mice in which the immune response to NM-081 cells was maximally destroyed and in which the immune response to MT-450 cells was maximally enhanced. These mice were selected for hybridoma production and were allowed to rest for 4 weeks before fusions were performed.
Monoclonal antibodies
Murine hybridomas were made by using the 30% PEG spinning method (Harlow and Lane, 1988) . SP2/0 myeloma cells were fused to immune spleen cells from two mice immunized by SI and boosted 5 days before the fusion was performed with 3610 6 MT-450 cells i.p. Hybridomas were screened by using NM-081 and MT-450 cells as targets in cell ELISA assays. Antibodies were prepared using conditioned medium from hybridomas as described (Harlow and Lane, 1988) . F(ab') 2 fragments were prepared using an Immunopure # F(ab') 2 preparation kit (Pierce, Netherlands).
Cell ELISA
Target cells were harvested using PBS/5 mM EDTA and resuspended at 2610 6 /ml in DMEM/10% FCS. Fifty ml of test antibody solutions were pipetted into wells of U form 96 well plates, and 50 ml aliquots of cells were then added. After incubation for 3 h at 48C, the cells were washed with PBS. Bound primary antibody was detected with rabbit-anti-mouse antibody coupled to horse radish peroxidase, followed by ABTS [2, 2' azino-di-(3-ethyl-benzthiazolin-sulphonate(6)] treatment (Harlow and Lane, 1988) .
Metastasis assays
Female w/Fu rats were injected subcutaneously with 5610 5 MT-450 cells in PBS. Animals were regularly monitored until their tumours grew to the German legal limit, or until they became moribund, at which time they were killed and an autopsy was performed. In antibody therapy experiments, the tumour cells were injected into the rats together with 200 mg antibody in PBS unless otherwise speci®ed. Thereafter, the animals received 200 mg antibody subcutaneously at the site of the tumour cell injection twice weekly for 4 weeks.
Immunohistochemistry
Strips of gastric and duodenal mucosae were resected from kidney donors 5 min after death, ®xed in 95% ethanol for 48 h and paran embedded. Rat tissues were ®xed in 4% paraformaldehyde then embedded in paran wax. Five mm sections were immunostained as described (Dall et al., 1995) . For immuno¯uorescence studies, adherent cells were grown on eight well chamber slides (Nunc) and suspension cultures were axed to silane treated slides using a Cytospin centrifuge (Shandon Southern). In both cases, cells on slides were washed with PBS, ®xed in 4% paraformaldehyde, then incubated for 30 min in PBS/10% FCS (FPBS). Antibody solution in FPBS was applied for 2 h. The cells were washed with PBS, then incubated for 1 h with Texas Red-labelled rabbit anti-mouse Ig diluted in FPBS. After two washes in PBS, the stained cells were mounted.
Cell labelling
Cells were labelled with L-35 S-methionine (500 mCi/ml) for 4 h as described (Sleeman, 1993) . Tunicamycin treated cells were incubated with 7.5 mg/ml tunicamycin for the indicated time. 
Immunoprecipitation
Radiolabelled cells were lysed in RIPA buer and aliquots were immunoprecipitated with 5 mg antibody as described (Sleeman et al., 1996) . For puri®cation of proteins binding to Ulex Europaeus I lectin, cells were lysed in PBS/1% NP40/ 1 mM PMSF, centrifuged, and the lysate incubated with Ulex Europaeus I lectin beads (Sigma) for 1 h at 48C. The beads were then washed three times with PBS and excess buer was removed. The beads were boiled in 1% SDS/20 mM phosphate pH 7.0. A 20-fold excess of RIPA buer was then added and the supernatant was used for immunoprecipitations after separation from the Ulex Europaea lectin beads. In experiments in which immunoprecipitated proteins were digested with 0.5 U N-glycosidase F, 2.5 mU Oglycosidase or 5 mU Neuraminidase (all purchased from Boehringer Mannheim), the antigen-antibody-bead complex was ®rst washed into 100 mM phosphate pH 7.0. Excess buer was removed, and the beads were then boiled for 5 min in 5 ml 1% SDS/20 mM phosphate pH 7.0. The enzymes were then added in 45 ml of 20 mM phosphate pH 7.0/1 mM CaSO 4 . Eective enzyme digestion was assured by reference to similar digestions of immunoprecipitated CD44v4-v7 protein, which is digested by each of these enzymes (Rudy et al., 1993) . Immunoprecipitated proteins were separated by SDS ± PAGE. Gels were treated with PPO as described (Sleeman, 1993) and exposed to X-ray ®lm.
Flow cytometry
Human erythrocytes of A1, A2, B and O blood groups were ®xed with 1% formaldehyde overnight at 48C. After washing with PBS, a 5% suspension was incubated for 30 min at 48C with 50 ml of antibody M-N#1 diluted at 1 mg/ml in 0.1% gelatin/PBS. After washing with 0.1% gelatin/PBS, erythrocytes were incubated for 30 min at 48C with FITC-labelled goat anti-mouse IgG (Bioatlantic, Nantes, France) in 0.1% gelatin/PBS. Cells were then washed with 0.1% gelatin/PBS and analysed on a FACScan (Becton Dickinson).
Adsorptions on synthetic oligosaccharides
Blood group related synthetic oligosaccharides (Table 4) coupled to a solid support (SYNSORB R ), were kindly provided by Chembiomed Ltd (Edmonton, Canada). M-N#1 antibody (0.2 mg in 200 ml of PBS containing 1% BSA) was incubated for 1 h at room temperature on 10 mg of SYNSORB R beads. A control for nonspeci®c adsorption was provided by beads without coupled oligosaccharide. After incubation, supernatants were collected and their reactivity toward blood group B salivary mucins was tested by ELISA as follows. Fresh saliva from a blood group B secretor and a blood group O secretor was heated in a boiling water bath for 15 min, then clari®ed by centrifugation at 13 000 g for 5 min. The saliva was diluted at 1/80 in 0.1 M carbonate buer, pH 9.0 and coated onto NUNC Immunoplates for 1 h at room temperature. After washing with PBS, wells were incubated with PBS containing 3% BSA. Supernatants of the M-N#1 bead adsorbtions were added in duplicate to wells coated with blood group B saliva. Non adsorbed M-N#1 was added in tetraplicate to wells coated with blood group B and blood group O saliva to give the maximum speci®c binding and the nonspeci®c binding respectively. After an overnight incubation at 48C, plates were washed with PBS and bound antibodies were detected using alkaline phosphatase-labelled goat anti mouse IgG (Sigma) and p-nitrophenylphosphate (Sigma).
